COVERAGE HUB
$LLY
5 articles in last 30 days
LAST 30 DAYS
5 articles
AVG GRADE
NEUTRAL
score: 0.00
SENTIMENT
BULLISH
TOTAL VIEWS
1
3-DAY GRADE TIMELINE
2026-06-12
TODAY
RECENT COVERAGE · 6 ARTICLES
Lilly acquires pain therapy developer 4E Therapeutics
Eli Lilly (LLY) has acquired 4E Therapeutics, a clinical-stage developer focused on pain management therapies. This transaction...
Kiran Mazumdar-Shaw eyes crown of world’s top insulin supplier for Biocon
Biocon's stated ambition to capture the world's largest insulin market share within five years signals a structural supply-side shift in...
Jim Cramer Wasn’t Selling Eli Lilly (LLY)
Eli Lilly (LLY) continues to garner favorable commentary from prominent market personalities, reinforcing its positioning within the...
10 Most Profitable Blue Chip Stocks to Buy According to Hedge Funds
Hedge fund positioning in blue-chip equities reflects confidence in earnings momentum heading into mid-2026. With S&P 500 companies...
Eli Lilly (LLY) Moves to Enforce 340B Claims Data Reporting Compliance
Eli Lilly (LLY) is enforcing compliance with 340B claims data reporting requirements by threatening to suspend discounted drug pricing...
Weekly Buzz: GH, LLY Gain FDA Nod; TEVA, GSK, Lead M&A Wave; ZEAL, LLY Post Strong Data
LLY, TEVA, GSK, and ZEAL are driving a significant biotech rally this week, anchored by multiple FDA and regulatory approvals across...
RELATED TICKERS